Related Experiment Videos
Dapsone agranulocytosis in a leprosy patient
1Department of Internal Medicine, J L N Hospital & Research Centre, (MP), India.
Leprosy Review
|September 1, 1994
Abstract:
Dapsone-induced agranulocytosis is a rare adverse effect. There are various reports of agranulocytosis in patients treated with dapsone for malaria prophylaxis and other dermatological diseases. However, this adverse reaction in leprosy is not often encountered. We describe agranulocytosis in a young patient who was taking dapsone (100 mg) for borderline-tuberculoid leprosy in a rural environment.
Insights
Dapsone can cause agranulocytosis, a rare but serious side effect. This case highlights the risk of agranulocytosis in patients treated with dapsone for leprosy, even at low doses.
Area of Science:
- Hematology
- Pharmacology
- Dermatology
Background:
- Dapsone is a key medication for treating leprosy.
- Agranulocytosis is a known rare adverse effect of dapsone.
- This reaction is documented in malaria prophylaxis and dermatological conditions.
Observation:
- A young patient was treated with dapsone (100 mg daily) for borderline-tuberculoid leprosy.
- The patient developed agranulocytosis during treatment.
- The case occurred in a rural healthcare setting.
Findings:
- Dapsone-induced agranulocytosis is infrequently reported in leprosy patients.
- This case underscores the potential for dapsone to cause agranulocytosis in leprosy treatment.
- Even low-dose dapsone (100 mg) can precipitate this severe adverse reaction.
Implications:
- Clinicians should maintain a high index of suspicion for agranulocytosis in patients on dapsone for leprosy.
- Awareness of this rare adverse effect is crucial for timely diagnosis and management.
- Monitoring blood counts may be warranted in specific patient populations or during prolonged dapsone therapy.